{
  "abstract": "Varicella-Zoster Virus (VZV) is a highly dermatotropic and neurotropic α-herpesvirus that causes varicella (chickenpox) during primary infection, subsequently establishing lifelong latency, and reactivates to cause herpes zoster when host immunity declines or suppressed. Recent large-scale epidemiological studies consistently associate herpes zoster immunization, particularly with the recombinant zoster vaccine (RZV), with a significantly reduced risk of incident dementia. These findings have prompted a rigorous re-evaluation of the infectious etiology of progressive neurodegeneration. This review integrates the intersecting molecular mechanisms of VZV latency, localized ganglionic immunosenescence, and systemic inflammaging. We critically evaluate a synergistic VZV-HSV-1 amyloidogenic cascade, while explicitly addressing the biological limitations of extrapolating these transient interactions to human central nervous system (CNS) neuropathology. Furthermore, we propose the hypothesis that AS01B-induced trained immunity may contribute to neuroprotection. Therefore, this review provides insight for understanding the systemic consequences of chronic VZV infection and the impact of adjuvant-mediated immune remodeling in aging populations.",
  "abstract_shown": true,
  "affiliations": [
    "Beijing ABZYMO Biosciences Co., Ltd.",
    "Jiangsu Recbio Technology Co.",
    "State Key Laboratory of Drug Regulatory Science (SKLDRS), National Institutes for Drug Control"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Lijun Zhang"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Shuang Wu"
    },
    {
      "affs": [
        2
      ],
      "name": "Yaru Quan"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Wenrong Yao"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/739t6rx2s632a.bib",
  "cited_by": 0,
  "doi": "10.3389/fimmu.2026.1953013",
  "fulltext_url": "https://europepmc.org/articles/PMC13714580",
  "id": "739t6rx2s632a",
  "issns": [
    "1664-3224"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1953013/full",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Review"
    ],
    [
      "openalex",
      "2713|Herpesvirus Infections and Treatments"
    ]
  ],
  "openalex": "W7221755180",
  "pdf_url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1953013/pdf",
  "pmcid": "PMC13714580",
  "pmid": "42953047",
  "published": "2026-10-14",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/739t6rx2s632a.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:17Z",
      "native_id": "10.3389/fimmu.2026.1953013",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1953013/full"
    },
    {
      "first_seen": "2026-10-31T00:20:41Z",
      "native_id": "MED:42953047",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42953047"
    },
    {
      "first_seen": "2026-11-01T12:22:03Z",
      "native_id": "PMC13714580",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fimmu.2026.1953013"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2713|Herpesvirus Infections and Treatments",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "VZV reactivation, immune remodeling, and dementia risk",
  "title_text": "VZV reactivation, immune remodeling, and dementia risk",
  "type": "peer-reviewed",
  "updated_at": "2026-11-01T12:22:03Z",
  "url": "https://research.draconitic.com/paper/739t6rx2s632a",
  "venue": "Frontiers in Immunology",
  "versions": []
}